Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | PRKCG | P05129 | 1/20 | 1.00 |
| ▸ | PRKCB | P05771 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daphnetin SCHEMBL128212 | 1.00 | MCL1 (1.00) | MCL1KDM4EALDH1A1MAPTALOX15 | |
| Daphnetin SCHEMBL29041019 | 0.98 | MCL1 (0.96) | MCL1KDM4EALDH1A1MAPTALOX15 | |
| Daphnetin SCHEMBL28897878 | 0.96 | MCL1 (0.92) | MCL1KDM4EALDH1A1MAPTALOX15 | |
| Daphnetin SCHEMBL28751158 | 0.96 | MCL1 (0.92) | MCL1KDM4EALDH1A1MAPTALOX15 | |
| Daphnetin SCHEMBL10427921 | 0.86 | MCL1 (0.74) | MCL1KDM4EALDH1A1MAPTALOX15 | |
| SCHEMBL4658019 | 0.81 | GAA (0.75) | MCL1KDM4EALDH1A1MAPTALOX15 | |
| Daphnetin SCHEMBL28664699 | 0.80 | MCL1 (0.64) | MCL1KDM4EALDH1A1MAPTALOX15 | |
| SCHEMBL4178185 | 0.79 | MCL1 (0.66) | MCL1KDM4EALDH1A1MAPTALOX15 | |
| SCHEMBL4178181 | 0.79 | MCL1 (0.66) | MCL1KDM4EALDH1A1MAPTALOX15 | |
| 8-Hydroxycoumarin SCHEMBL1366927 | 0.77 | MCL1 (0.62) | MCL1KDM4EALDH1A1MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215355-B2 | Stem cell derived islet differentiation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-02-04 | — | — | US | claimed |
| CN-114652713-B | Mycobacterium tuberculosis isocitrate lyase lead inhibitor | 重庆医科大学国际体外诊断研究院 | 2024-07-23 | — | — | CN | claimed |
| CN-115634715-A | Photocatalyst for degrading organic pollutants and preparation method thereof | 扬州工业职业技术学院 | 2023-01-24 | — | — | CN | claimed |
| CN-114652713-A | Mycobacterium tuberculosis isocitrate lyase lead inhibitor | 重庆医科大学国际体外诊断研究院 | 2022-06-24 | — | — | CN | claimed |
| CN-112552289-B | Near-infrared fluorescent probe substrate of COMT and application thereof | 无锡尔云科技有限公司 | 2022-03-11 | — | — | CN | claimed |
| WO-2026087419-A1 | PROCESS TO EFFICIENTLY RELEASE SUGARS AND/OR PHENOLIC COMPOUNDS FROM PLANT MATERIAL | UNIVERSITEIT GENT (BE) | 2026-04-30 | — | — | WO | disclosed |
| US-20260053859-A1 | GENETICALLY ENGINEERED CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260028591-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260022345-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025235400-A1 | NOVEL ISLET POTENCY ASSAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025235403-A1 | DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4612275-A2 | GENETICALLY ENGINEERED CELLS | Vertex Pharmaceuticals Incorporated (US) | 2025-09-10 | — | — | EP | disclosed |
| US-11466256-B2 | Stem cell derived islet differentiation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-10-11 | — | — | US | disclosed |
| CN-111808059-B | Tumor diagnosis and treatment fluorescent probe targeting tumor Woberg effect | 天津大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-114751854-A | Near-infrared fluorescent probe and preparation method and application thereof | 中国科学院自动化研究所 | 2022-07-15 | — | — | CN | disclosed |
| CN-114652713-A | Mycobacterium tuberculosis isocitrate lyase lead inhibitor | 重庆医科大学国际体外诊断研究院 | 2022-06-24 | — | — | CN | disclosed |
| CN-114652713-A | Mycobacterium tuberculosis isocitrate lyase lead inhibitor | 重庆医科大学国际体外诊断研究院 | 2022-06-24 | — | — | CN | disclosed |
| CN-114558032-A | Method for preparing platelets from pluripotent stem cells and composition thereof | 安斯泰来再生医药协会 | 2022-05-31 | — | — | CN | disclosed |
| CN-112552289-B | Near-infrared fluorescent probe substrate of COMT and application thereof | 无锡尔云科技有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-112552289-B | Near-infrared fluorescent probe substrate of COMT and application thereof | 无锡尔云科技有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028591-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | IAPP, CTNND1, CTNNBL1 | MCL1 1140/4885KDM4E 1158/4885ALDH1A1 1565/4885 |
| US-20260053859-A1 | GENETICALLY ENGINEERED CELLS | CD47, IAPP, B2M | MCL1 1188/4885KDM4E 1387/4885ALDH1A1 2224/4885 |
| US-20260022345-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | IAPP, PNLIP, CTNND1 | MCL1 985/4885KDM4E 1127/4885ALDH1A1 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.